Graft vs Host Disease (GvHD) models can form a vital part of oncology drug development plans. Charles River offers two types of preclinical Graft vs Host Disease model: allogeneic and xenogeneic. These models can be used;
- To Identify new drugs for the treatment of Graft vs Host Disease
- As a pharmacodynamic (PD) screening platform to evaluate the ability of immunoregulatory drugs to modulate the disease progression
- As an in vivo screening platform to assess the MOA of drugs that mediate either immunosuppression or immune activation/potentiation
Download our data, and contact us to discuss your project or with any questions you may have at 1.877.CRIVER.1 (1.877.274.8371).